CONTRAVE®
November 4, 2025
Press Releases
CONTRAVE®
October 28, 2025
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
See moreCURRAX PHARMACEUTICALS LLC
October 23, 2025
Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
See moreCURRAX PHARMACEUTICALS
August 5, 2025
Currax Announces National Expansion of “Cravings Don’t Own Me” CTV Commercial, Along with Launch of New “Real Patients, Real Results” DTC Campaign
See moreContrave®
July 15, 2025
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
See moreCONTRAVE®/MYSIMBA
March 20, 2025
Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site
See moreCONTRAVE®/MYSIMBA®
March 11, 2025
Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA®
See moreCURRAX PHARMACEUTICALS
February 25, 2025
Currax Provides Update on Litigation Against Found Health Inc.
See moreCURRAX PHARMACEUTICALS
January 10, 2025